|Phase III, Phase II||Treatment||Closed||18 and over||Pharmaceutical / Industry||CC-5013-DLC-001|
The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.
Further Study Information
This research study is for patients who have been diagnosed with Diffuse Large B-cell Lymphoma (DLBCL) that did not respond to (refractory) or that has come back after chemotherapy treatment (relapsed). Lymphoma is a cancer of a type of blood cell called lymphocytes. Diffuse Large B-cell Lymphoma (DLBCL)is just one type of lymphoma. Within Diffuse Large B-cell Lymphoma (DLBCL) there are two different subtypes called GCB and non-GCB which can be determined by cell surface marker tests or by gene expression tests. Scientists can look at cells and genes in the laboratory and see that the two kinds are different, but they don't know yet what the difference means. To patients and to doctors these two kinds seem the same. Right now doctors don't usually do tests to find out which kind a patient has because the treatment is the same for both.
This study will have two stages, 1 and 2. The main purpose of Stage 1 is to separate patients by subtype and then test whether patients taking lenalidomide or any one of four other drugs have a better response. It is possible that lenalidomide will work better than one of the other drugs in zero, one, or both subtypes. Stage 2 will further test only the subtype(s) from Stage 1 that showed a good response to lenalidomide. The main purpose of Stage 2 is to test how long patients are disease free on lenalidomide compared to one of the four other drugs.
- Histologically proven Diffuse Large B-Cell Lymphoma (DLBCL).
- Relapsed or refractory to combination chemotherapy for Diffuse Large B-Cell Lymphoma (DLBCL) that contains rituximab and an anthracycline, and one additional combination chemotherapy or stem cell transplant.
- Measurable Diffuse Large B-Cell Lymphoma (DLBCL)disease by Computed Tomograph(CT) / Magnetic Resonance Imagining (MRI).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
- Diagnosis of lymphoma histologies other than Diffuse Large B-Cell Lymphoma (DLBCL).
- History of malignancies, other than Diffuse Large B-Cell Lymphoma (DLBCL), unless the patient has been disease free for 3 years or more.
- Eligible for autologous stem cell transplant.
- Known seropositive for, or history of, active Human Immunodeficiency Virus (HIV) Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)
- Neuropathy grade 4.
Trial Lead Organizations/Sponsors
|Oliver Manzke, MD||Study Director|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01197560
ClinicalTrials.gov processed this data on March 05, 2014
Back to Top